Hematology

With a long history of advancing hematology research, we’re your partner in the rapidly changing world of hematopoietic stem cell transplantation (HSCT) and cellular and gene therapies.

We’re particularly proud to have partnered with a client to successfully run Phase I and Phase II trials, establishing dosing and proof of concept for a compound with the potential to become the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S.

Cell and Gene Therapy

With a foundation built on decades of research and collaboration with leading investigators, our Cell and Gene Therapy team brings more than 45 years of invaluable expertise in conducting clinical trials to our customers.

Our innovations are unlocking real research potential to test and create life-changing treatments for patients suffering from a wide range of conditions and diseases.

Why Emmes?

Leadership

Through the knowledge of our leadership team, Emmes Group envisions a future where clinical research is not only advanced, but transformed. We strive to be at the forefront of scientific discovery, pioneering new ways to integrate technology, AI and human expertise for the betterment of healthcare worldwide. Together we are committed to fostering innovation, scientific excellence, and the seamless integration of technology into the fabric of clinical research.

Ophthalmology

Ophthalmology

Our innovative therapeutic solutions have already improved the lives of millions.

Find out how we’re shaping the treatment landscape for ophthalmology patients and ask how our global experience in age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and several rare eye diseases, can help you.

Rare Disease

We turn patient voices into better data

We are focused on urgently accelerating the clinical development of new treatments in rare diseases.

Combining our industry knowledge, alongside personal experience within rare disease clinical trials, makes us a more valuable research partner for Sponsors looking for a truly tailored service experience.

Oncology

With approximately a quarter of all clinical trials and up to 40% of drugs in the development pipeline focused on oncology, each day seems to bring innovations in research that result in new therapies for cancer patients.

Clinical Neuroscience

Our client collaborations have been enhancing clinical practice and treatment of neurological and psychiatric disorders for decades, positively impacting human health, public policy and the testing of innovative therapeutic solutions.

Our Phase I-IV clinical trial research services can advance your neuroscience research program, from protocol development to regulatory submissions and publications, and we offer particular expertise in Alzheimer’s disease, multiple sclerosis, epilepsy, traumatic brain injury, stroke, major depression

Subscribe to